BEVERLY WILSHIRE LTD.

(Incorporated in the Republic of Singapore)
(Company Registration Number: 200505118M)

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THIRD QUARTER AND FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026

TABLE OF CONTENTS

		Page
A.	Condensed interim consolidated statements of comprehensive income	1
B.	Condensed interim consolidated statements of financial position	2
C.	Condensed interim consolidated statements of cash flows	3
D.	Condensed interim statements of changes in equity	4-8
E.	Notes to the condensed interim consolidated financial statements	8-20
F.	Other information pursuant to Appendix 7C of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist	20-27

---

*The quarterly reporting of financial statements is mandatory for Beverly Wilshire Ltd. pursuant to Rule 705(2) of the Singapore Exchange Securities Trading Limited's Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**"). The foregoing statement is made pursuant to Rule 705(2C) of the Catalist Rules.*

This document has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Center, Singapore 068914.

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year

A. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

		Group					
		3 months			9 months		
		1 Jul 2026 to 30 Sep 2026	1 Jul 2025 to 30 Sep 2025	**+/ (-)**	**1 Jan 2026 to 30 Sep 2026**	1 Jan 2025 to 30 Sep 2025	**+/ (-)**
	Note	**S$'000**	S$'000		**S$'000**	S$'000	
Revenue	4.2	**1,283**	2,597	(51%)	**4,261**	6,967	(39%)
Cost of Sales		**(604)**	(1,129)	(47%)	**(1,902)**	(3,052)	(38%)
Gross Profit		**679**	1,468	(54%)	**2,359**	3,915	(40%)
Gross Profit Margin		**53%**	57%	(4%)	**55%**	56%	(1%)
Other income		**288**	152	90%	**358**	440	(18%)
Distribution expenses		**(17)**	(386)	(96%)	**(47)**	(854)	(94%)
Administrative expenses		**(1,114)**	(1,135)	(2%)	**(3,148)**	(3,289)	(4%)
Finance expenses		**(26)**	(25)	4%	**(74)**	(83)	(11%)
Profit/(Loss) before income tax		**(190)**	74	N.M.	**(552)**	129	N.M.
Income tax credit		**-**	-	N.M.	**-**	-	N.M.
Profit/(Loss) after income tax		**(190)**	74	N.M.	**(552)**	129	N.M.
Other comprehensive income/(loss), net of tax:							
Exchange differences on translation of foreign operations		**(18)**	(61)	N.M.	**15**	(33)	N.M.
Total comprehensive income/(loss)		**(208)**	13	N.M.	**(537)**	96	N.M.
Total income/(loss) attributable to:							
Equity holders of the Company		**(183)**	29	N.M.	**(547)**	61	N.M.
Non-controlling interests		**(7)**	45	N.M.	**(5)**	68	N.M.
		(190)	74	N.M.	**(552)**	129	N.M.
Total comprehensive income/(loss) attributable to:							
Equity holders of the Company		**(201)**	(32)	N.M.	**(532)**	28	N.M.
Non-controlling interests		**(7)**	45	N.M.	**(5)**	68	N.M.
		(208)	13	N.M.	**(537)**	96	N.M.

N.M.: Not Meaningful

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

B. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

		Group		Company	
		As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
ASSETS		**S$'000**	S$'000	**S$'000**	S$'000
Current assets	**Note**				
Cash and bank balances		**129**	572	**106**	235
Trade and other receivables	7	**3,622**	3,484	**265**	241
Inventories		**370**	391	**-**	-
		4,121	4,447	**371**	476
Non-current assets					
Investment in subsidiaries	9	**-**	-	**6,463**	6,400
Property, plant and equipment	10	**476**	599	**232**	283
Intangible assets	11	**661**	653	**-**	-
		1,137	1,252	**6,695**	6,683
Total assets		**5,258**	5,699	**7,066**	7,159
LIABILITIES					
Current liabilities					
Trade and other payables	12	**3,720**	4,077	**787**	1,141
Income tax payable		**6**	6	**-**	-
Borrowings	13(b)	**-**	9	**457**	466
Lease liabilities	13(a)	**166**	342	**70**	66
		3,892	4,434	**1,314**	1,673
Non-current liabilities					
Borrowings	13(b)	**720**	415	**720**	415
Lease liabilities	13(a)	**575**	667	**161**	214
Deferred income tax liabilities		**10**	15	**-**	-
		1,305	1,097	**881**	629
Total liabilities		**5,197**	5,531	**2,195**	2,302
Net assets		**61**	168	**4,871**	4,857
EQUITY					
Capital and reserves attributable to equity holders of the Company					
Share capital	14	**93,678**	93,248	**93,678**	93,248
Settlement shares and warrants receivables	8	**(3,557)**	(3,557)	**(3,557)**	(3,557)
Other reserves		**(68)**	(83)	**133**	133
Accumulated losses		**(89,131)**	(88,584)	**(85,383)**	(84,967)
		922	1,024	**4,871**	4,857
Non-controlling interests		**(861)**	(856)	**-**	-
Total equity		**61**	168	**4,871**	4,857

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year

C. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

	Group			
	3 months ended		**9 months ended**	
	30 Sep 2026	30 Sep 2025	**30 Sep 2026**	30 Sep 2025
	S$'000	S$'000	**S$'000**	S$'000
Cash flows from operating activities				
Profit/(Loss) before tax	**(190)**	74	**(552)**	129
Adjustments for:				
Depreciation of property, plant and equipment	**151**	143	**453**	406
Write-off of property, plant and equipment	**6**	-	**7**	-
Write-back of payable	**(288)**	-	**(288)**	-
Gain arising from lease termination	**-**	(43)	**-**	(43)
Gain arising from lease modification	**-**	-	**(61)**	-
Share based payment	**-**	-	**-**	25
Unrealised currency translation (gain)/loss	**(3)**	(68)	**(6)**	(60)
Finance expenses	**26**	25	**74**	83
Operating profit/(loss) before working capital changes	**(298)**	131	**(373)**	540
Change in working capital:				
Trade and other receivables	**(157)**	(204)	**(138)**	(442)
Inventories	**(10)**	(8)	**20**	14
Trade and other payables (*)	**207**	342	**(63)**	(1,252)
Cash used in operations	**(258)**	261	**(554)**	(1,140)
Interest expense - bank overdrafts	**-**	-	**-**	-
Net cash used in operating activities	**(258)**	261	**(554)**	(1,140)
Cash flows from investing activities				
Purchase of property, plant and equipment	**(9)**	(5)	**(13)**	(21)
Net cash used in investing activities	**(9)**	(5)	**(13)**	(21)

	Group			
	3 months ended		9 months ended	
	30 Sep 2026	30 Sep 2025	**30 Sep 2026**	30 Sep 2025
	S$'000	S$'000	**S$'000**	S$'000
Cash flows from financing activities				
Proceeds from issuance of shares	**-**	-	**275**	1,600
Non-controlling interest contribution	**-**	-	**-**	-
Share issuance expenses	**-**	-	**(9)**	-
Proceeds from borrowings	**400**	-	**400**	118
Repayment of lease liabilities	**(186)**	(198)	**(449)**	(577)
Repayment of borrowings	**(44)**	(54)	**(93)**	(290)
Interest paid	**-**	-	**-**	-
Net cash generated from / (used in) financing activities	**170**	(252)	**124**	851
Net increase/(decrease) in cash and cash equivalents	**(97)**	4	**(443)**	(310)
Cash and cash equivalents at the beginning of the financial period	**226**	544	**572**	858
Cash and cash equivalents at the end of the financial period	**129**	548	**129**	548
Consolidated cash and cash equivalents are represented by:				
Cash and bank balances	**129**	548	**129**	548
Less: fixed deposits pledged	**-**	-	**-**	-
	129	548	**129**	548
Less: bank overdrafts	**-**	-	**-**	-
Cash and cash equivalents per consolidated statements of cash flows	**129**	548	**129**	548

* *Subsequent to the publication of the 2Q FY2026 results, corrections of errors were made involving (i) the reclassification of S$61k between "Trade and Other Payables" and "Repayment of Lease Liabilities"; and (ii) the adjustment of S$164k relating to non-cash share issuances for debt capitalisation and the settlement of professional fees, which had been incorrectly included in financing cash flows. The 3Q FY2026 figures are correct and remain unchanged.*

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

D.CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

Group	Share capital S$'000	Settlement shares and warrants receivables S$'000	Currency translation reserves S$'000	Accumulated losses S$'000	Share option reserves S$'000	Warrant reserves S$'000	Equity attributable to owners of the Company S$'000	Non-controlling interests S$'000	Total (capital deficiency)/ equity S$'000
Balance as at 1 January 2026	**93,248**	**(3,557)**	**(216)**	**(88,584)**	**-**	**133**	**1,024**	**(856)**	**168**
Net loss for the financial period	**-**	**-**	**-**	**(547)**	**-**	**-**	**(547)**	**(5)**	**(552)**
Other comprehensive income	**-**	**-**	**15**	**-**	**-**	**-**	**15**	**-**	**15**
Total comprehensive loss for the financial period	**-**	**-**	**15**	**(547)**	**-**	**-**	**(532)**	**(5)**	**(537)**
Issuance of share capital	**430**	**-**	**-**	**-**	**-**	**-**	**430**	**-**	**430**
Expiry of warrants	**-**					**-**			
Total transactions with owners, recognised directly in equity	**430**	**-**	**-**	**-**	**-**	**-**	**430**	**-**	**430**
Balance as at 30 Sep 2026	**93,678**	**(3,557)**	**(201)**	**(89,131)**	**-**	**133**	**922**	**(861)**	**61**
Balance as at 1 January 2025	87,630	(3,557)	(137)	(88,630)	-	229	(4,465)	(877)	(5,342)
Net profit for the financial period	-	-	-	61	-	-	61	68	129
Other comprehensive income	-	-	(33)	-	-	-	(33)	-	(33)
Total comprehensive income for the financial period	-	-	(33)	61	-	-	28	68	96
Issue of share capital	2,479	-	-	-	-	-	2,479	-	2,479
Expiry of warrants	96					(96)			
Total transactions with owners, recognised directly in equity	2,575	-	-	-	-	(96)	2,479	-	2,479
Balance as at 30 Sep 2025	90,205	(3,557)	(170)	(88,569)	-	133	(1,958)	(809)	(2,767)

D.CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (cont'd)

Company	Share capital S$'000	Settlement shares and warrants receivables S$'000	Accumulated losses S$'000	Warrant reserves S$'000	Total equity S$'000
Balance as at 1 January 2026	**93,248**	**(3,557)**	**(84,967)**	**133**	**4,857**
Loss for the financial period	**-**	**-**	**(416)**	**-**	**(416)**
Issuance of share capital	**439**	**-**	**-**	**-**	**439**
Shares issuance expenses	**(9)**	**-**	**-**	**-**	**(9)**
Total transactions with owners, recognised directly in equity	**430**	**-**	**-**	**-**	**430**
Balance as at 30 Sep 2026	**93,678**	**(3,557)**	**(85,383)**	**133**	**4,871**
Balance as at 1 January 2025	87,630	(3,557)	(83,599)	229	703
Loss for the financial period	-	-	(858)	-	(858)
Issuance of share capital	2,479	-	-	-	2,479
Expiry of warrants	96	-	-	(96)	-
Total transactions with owners, recognised directly in equity	2,575	-	-	(96)	2,479
Balance as at 30 Sep 2025	90,205	(3,557)	(84,457)	133	2,324

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

During the three months' financial period ended 30 September 2026, there has been no change in the issued and paid-up share capital of the Company.

The number of outstanding convertibles as at 30 September 2026 was 5,294,342 (30 September 2025: 5,294,342). As at 30 September 2026, the number of new ordinary shares that may be issued on conversion of all the outstanding convertibles was 5,294,342 (30 September 2025: 5,294,342), which represented approximately 0.44% (30 September 2025: 0.58%) of the total issued shares of the Company.

The Company did not have any treasury shares or subsidiary holdings as at 30 September 2026 and 30 September 2025.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year

The total number of issued ordinary shares (excluding treasury shares) as at 30 September 2026 was 1,192,022,722 (31 December 2025: 1,151,998,391).

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on

Not applicable. The Company did not have any treasury shares during the financial period ended and as at 30 September 2026.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on

Not applicable. The Company did not have any subsidiary holdings during the financial period ended and as at 30 September 2026.

E. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate information

Beverly Wilshire Ltd. (the "**Company**") is incorporated in Singapore (Registration No: 200505118M) with its principal place of business and registered office at 160 Robinson Road, #05-08 SBF Center, Singapore 068914. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 13 April 2006.

The principal activities of the Company are those of investment holding and provision of management services.

The principal activities of its subsidiaries are aesthetic medical and healthcare, as disclosed in Note 9 to the condensed interim consolidated financial statements.

2. Basis of preparation

The condensed interim consolidated financial statements for the nine months ended 30 September 2026 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)**") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore.

The condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the financial position and financial performance of the Group since the last financial statements for the financial year ended 31 December 2025.

The accounting policies and method of computation adopted are consistent with the most recent audited financial statements for the financial year ended 31 December 2025, which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1 of the condensed interim consolidated financial statements.

The condensed interim consolidated financial statements are presented in Singapore dollar, which is the Company's functional currency. All financial information is rounded to the nearest thousand (S$'000) except otherwise indicated.

2.1 New and amended standards adopted by the Group

There has been no change in the accounting policies and methods of computation adopted by the Group for the current reporting period compared with the audited financial statements for the financial year ended 31 December 2025, except for the adoption of new or revised SFRS(I) and Interpretations of SFRS (I) ("**INT SFRS (I)**") that are mandatory for the financial year beginning on or after 1 January 2026. The adoption of these SFRS (I) and INT SFRS (I) has no significant impact on the Group.

2.2 Critical accounting estimates, assumptions and judgements

In preparing the condensed interim consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited consolidated financial statements in and for the financial year ended 31 December 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

2.3 Going concern

The Group reported a net loss of S$552,000 (2025: net profit of S$129,000) and the Company incurred a net loss of S$416,000 (2025: S$858,000) for the nine months ended 30 September 2026, respectively. As at 30 September 2026, the Group's current assets and current liabilities amounted to S$4,121,000 (31 December 2025: S$4,447,000) and S$3,892,000 (31 December 2025: S$4,434,000) respectively.

The Board of Directors believes that the use of the going concern assumption in preparing the consolidated financial statements of the Group and the statement of financial position of the Company for the financial period ended 30 September 2026 is appropriate after taking into consideration the following assumptions and measures:

(i) Since 31 December 2025 and up to the date of this announcement, the Company has raised additional capital amounting to S$275,000 through the issuance of new ordinary shares upon the completion of share subscription agreements as announced on 29 January 2026.

(ii) On 29 January 2026, the Board approved the capitalisation of debts pertaining to outstanding remuneration of S$64,000 and professional fees amounting to S$100,000. These amounts are no longer payable in cash and will not result in cash outflows within the next 12 months.

(iii) The Company has received a financial support undertaking letter from Dato' Ng Tian Sang @ Ng Kek Chuan, whereby he will undertake, for as long as he is a controlling shareholder of the Company, to provide continuing financial cash flow support to the Group to enable it to continue its operations as a going concern and to meet its liabilities as and when they fall due for the next 18 months.

(iv) Barring unforeseen circumstances, key operating subsidiaries in Malaysia will continue their operations for the next 18 months without additional funding from the Company.

(v) The financial performance of the aesthetic medical and healthcare segment in Malaysia is expected to continue to improve.

(vi) Subject to obtaining the permission and necessary approvals of SGX-ST, the Company also intends to raise additional funds of more than S$2 million via equity and debt instruments to augment the Group's cashflows for working capital. The Company will make further announcements relating to such fund-raising matters as appropriate from time to time.

(vii) The Company is intending to make further acquisitions, which, if and when completed, are expected to generate additional revenue for the Group to support the Group's cashflow, and to ensure that the Group can continue to operate as a going concern.

3. Seasonal operations

The Group's businesses were not affected significantly by seasonal or cyclical factors during the financial period reported on.

4. Segment and revenue information

The Group is organised into two reportable segments as described below, which are the Group's strategic business units. The strategic business units offer different services, and are managed separately because they require different marketing strategies. For each of the strategic business units, the Board of Directors reviews the internal management reports on a quarterly basis. The following summary describes the operations in each of the Group's reportable segments:

Aesthetic medical and healthcare:	Provision of aesthetic medical services, including the provision of aesthetic medical, beauty and wellness services.
Investment and others:	Business of investment holding, provision of management services and provision of marketing, distribution and related services.

4.1 Reportable Segments

Segment revenue and results

Group	Aesthetic medical and healthcare	Investment and others	Total
	S$'000	**S$'000**	**S$'000**
9 months ended 30 Sep 2026			
Segment revenue			
- External parties	**4,261**	**-**	**4,261**
Gross profit	**2,359**	**-**	**2,359**
Other income	**70**	**288**	**358**
Expenses			
- Distribution	**(47)**	**-**	**(47)**
- Administrative	**(2,381)**	**(767)**	**(3,148)**
- Finance	**(34)**	**(40)**	**(74)**
Profit/ (Loss) before income tax	**(33)**	**(519)**	**(552)**
Income tax credit	**-**	**-**	**-**
Profit/ (Loss) after income tax	**(33)**	**(519)**	**(552)**

	Aesthetic medical and healthcare	Investment and others	Total
	S$'000	S$'000	S$'000
9 months ended 30 Sep 2025			
Segment revenue			
- External parties	6,967	-	6,967
Gross profit	3,915	-	3,915
Other income	435	5	440
Expenses			
- Distribution	(854)	-	(854)
- Administrative	(2,369)	(920)	(3,289)
- Finance	(47)	(36)	(83)
Profit/(Loss) before income tax	1,080	(951)	129
Income tax credit	-	-	-
Profit/(Loss) after income tax	1,080	(951)	129

Segment Assets and Liabilities

Group	Aesthetic medical and healthcare	Investment and others	Total
	S$'000	**S$'000**	**S$'000**
As at 30 Sep 2026			
Assets and liabilities			
Segment and consolidated total assets	**4,655**	**603**	**5,258**
Consolidated total assets			**5,258**
Segment and consolidated total liabilities	**3,002**	**2,195**	**5,197**
Consolidated total liabilities			**5,197**

	Aesthetic medical and healthcare	Investment and others	Total
	S$'000	S$'000	S$'000
As at 31 December 2025			
Assets and liabilities			
Segment and consolidated total assets	4,939	760	5,699
Consolidated total assets			5,699
Segment and consolidated total liabilities	3,690	1,841	5,531
Consolidated total liabilities			5,531

4.2 Disaggregation of revenue

	Group	
	9 months ended	
	30 Sep 2026	30 Sep 2025
	S$'000	S$'000
At a point in time		
Aesthetic medical and healthcare		
- Malaysia	**4,261**	6,967

5. Financial instruments

The following table sets out the financial assets and liabilities as at the end of the reporting period:

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	S$'000	S$'000	**S$'000**	S$'000
Financial assets				
Amortised cost	**3,485**	3,800	**166**	284
Financial liabilities				
Amortised cost	**4,141**	3,975	**1,964**	2,022
Lease liabilities	**741**	1,009	**231**	280

6. Profit before taxation

Significant items

	Group			
	3 months ended		**9 months ended**	
	30 Sep 2026	30 Sep 2025	**30 Sep 2026**	30 Sep 2025
	S$'000	S$'000	**S$'000**	S$'000
Income				
Rental income	**-**	99	**-**	360
Government grants	**-**	-	**-**	6
Gain on lease modification	**-**	-	**61**	-
Gain on lease termination	**-**	43	**-**	43
Write-back of payable	**288**	-	**288**	-
Expenses				
Depreciation of property, plant and equipment	**(151)**	(143)	**(453)**	(406)
Write-off of property, plant and equipment	**(6)**	-	**(7)**	-
Interest expenses	**(26)**	(25)	**(74)**	(83)

7. Trade and other receivables

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	S$'000	S$'000	**S$'000**	S$'000
Trade receivables				
- Non-related parties	**370**	329	**-**	-
	370	329	**-**	-
Less: Loss allowance	**(308)**	(308)	**-**	-
	62	21	**-**	-
Other receivables				
- Subsidiaries	**-**	-	**1,202**	1,170
- Non-related parties	**173**	182	**7**	28
	173	182	**1,209**	1,198
Less: Loss allowance	**(52)**	(52)	**(1,170)**	(1,170)
	121	130	**39**	28
Deposits	**3,173**	3,077	**21**	21
Prepayments	**266**	256	**205**	192
	3,622	3,484	**265**	241

8. Settlement shares and warrants receivables

During the financial year ended 31 December 2020, the Directors of the Company approved the plan to unwind the acquisition of Brand X Lab Pte Ltd ("**Brand X**"). Subsequently, on 16 February 2021, the Company entered into an unwinding and settlement agreement (the "**Agreement**") with Tan Suying ("**TSY**") in respect of the mutual agreement by TSY and the Company to unwind the acquisition of Brand X.

On 18 January 2022, TSY and the Company entered into a supplemental agreement (the "**Supplemental Agreement**") to amend, modify and vary the terms and provisions of the Agreement. The key modifications to the Agreement are summarised below:

- TSY to refrain from exercising the voting rights and transfer of the consideration shares and warrants that she received from the acquisition;
- The methods for unwinding of the acquisition shall be by way of capital reduction pursuant to Division 3A (Part IV) of the Companies Act, and subject always to due compliance with and observation of the applicable provisions of the Catalist Rules of the SGX-ST and the Constitution of the Company which shall result in the cancellation of the 31,666,666 ordinary shares of the Company held by TSY as part of the consideration for the disposal and transfer of the 100,000 ordinary shares of Brand X to TSY. Selective off-market share buy-back as a method of unwinding of the acquisition was removed;
- TSY and the Company shall endeavor to complete the unwinding of the acquisition by no later than 31 August 2022 and if this is not achieved, both parties shall provide assistance for completion as soon as possible without any limit in time;

- The mutual agreement to unwind the acquisition is irrevocable and neither TSY nor the Company shall be entitled or have the right to terminate the Agreement and the unwinding of the acquisition; and
- The date of effective transfer of any and all rights and entitlements as well as any and all obligations attached to the 100,000 ordinary shares of Brand X, being the sale shares, shall remain 1 January 2021 or such earliest date permissible under applicable laws and regulations as well as the financial reporting standards.

Accordingly, Brand X was de-consolidated from 1 January 2021. The fair value of the consideration receivable for the unwinding of Brand X amounted to S$3,557,000 was classified as "Settlement shares and warrants receivables" on the Company and Group's balance sheet on 1 January 2021 and as at 31 December 2025 and 30 September 2026.

9. Investment in subsidiaries

	Company	
	As at 30 Sep 2026	As at 31 Dec 2025
	S$'000	S$'000
Unquoted equity shares, at cost	**6,463**	6,400

Details of the Group's subsidiaries are as follows:

Name of subsidiary	Principal activities	Country of incorporation and operation	Effective equity interest of the Group	
			As at 30 Sep 2026	As at 31 Dec 2025
			%	%
Albedo Corporation Pte. Ltd.	To carry on the business of general merchants, importers, exporters, commission agents and dealers in raw materials, consumables, instruments and semi-finished products for steel mills, iron and steel foundries and aluminium smelters in the Asia- Pacific region	Singapore	**100**	100
JCG-Beverly Pte. Ltd.	Investment holding and provision of management services	Singapore	**100**	100
Beverly Wilshire Medical Centre Sdn. Bhd.	Provision of cosmetic and plastic surgery, health screening and as medical specialist centre with out-patient and day care services and activities	Malaysia	**95.25**	95.25
Beverly Wilshire Medical Centre (JB) Sdn. Bhd.	Provision of aesthetic and cosmetic surgery and reconstructive surgery	Malaysia	**100**	100

Beverly Wilshire Tropicana City Mall Sdn. Bhd.	Provision of cosmetological and aesthetical related treatments	Malaysia	**100**	100
Beverly Wilshire Aesthetic Dental Centre Sdn. Bhd	Provision of aesthetic dental care	Malaysia	**100**	100
Beverly Wilshire Hair Transplant Sdn. Bhd.	Provision of hair transplant care	Malaysia	**51**	51
Beverly Dentistree Sdn. Bhd	Provision of aesthetic dental care	Malaysia	**70**	70
Beverly Wilshire Medical Academy and Research Centre Sdn. Bhd.	Provision of aesthetic, cosmetic and plastic surgery, healthy aging therapy, health screening and wellness and medical research	Malaysia	**98.32**	98.32
Beverly Ipoh Sdn. Bhd.	Provision of aesthetic medicine and related activities	Malaysia	**70**	70
Natasha Beverly Sdn. Bhd.	Provision of physiotherapy, spa, reflexology services and activities	Malaysia	**56**	56
Beverly Wilshire Cosmetic Surgery Centre Sdn. Bhd.	Provision of cosmetic and plastic surgery treatment and services	Malaysia	**95.25**	95.25
Natasha Beverly Dental Sdn. Bhd.	Provision of aesthetic dental services	Malaysia	**45.36**	45.36
Natasha Beverly Mizu Sdn. Bhd.	Provision of healthy aging, regenerative medicine, health screening services and medical spa procedures	Malaysia	**39.20**	39.20
Natasha Beverly Aesthetics Sdn. Bhd.	Provision of aesthetic medicine and related activities	Malaysia	**31.36**	31.36
Beverly Bangsar Sdn Bhd	Provision of aesthetic medical services	Malaysia	**100**	100
Beverly Wilshire Aesthetics & Wellness Pte. Ltd.	Provision of clinics and other general medical services	Singapore	**70**	70
Beverly Wilshire Beauty Pte. Ltd.	Provision of beauty salons and SPAs	Singapore	**100**	100

10. Property, plant and equipment

During the financial period ended 30 September 2026, the Group acquired property, plant and equipment amounting to S$13,000 (31 December 2025: S$54,000).

11. Intangible assets

	Group	
	As at 30 Sep 2026	As at 31 Dec 2025
	S$'000	S$'000
Goodwill arising on consolidation	**661**	653
	661	653

12. Trade and other payables

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	S$'000	S$'000	**S$'000**	S$'000
Trade payables				
- Non-related parties	**254**	265	**-**	-
Other payables				
- Non-related parties	**985**	1,395	**200**	679
- Related parties	**52**	48	**-**	-
Contract liabilities	**299**	526	**-**	-
Amount due to directors	**949**	857	**-**	-
Accruals for operating expenses	**1,181**	986	**587**	462
	3,720	4,077	**787**	1,141

13. Borrowings

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	S$'000	S$'000	**S$'000**	S$'000
(a) Lease liabilities				
Current	**166**	342	**70**	66
Non-current	**575**	667	**161**	214
	741	1,009	**231**	280

13. Borrowings (cont'd)

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	S$'000	S$'000	**S$'000**	S$'000
(b) Borrowings				
Current				
- Loan 1	**-**	-	**457**	466
- Loan 2	**-**	-	**-**	-
- Loan 3	**-**	9	**-**	-
	-	9	**457**	466
Non-current				
- Loan 2	**320**	415	**320**	415
- Loan 4	**400**	-	**400**	-
	720	415	**720**	415
Total	**720**	424	**1,177**	881

Borrowings (current) refers to amounts repayable in one year or less. Borrowings (non-current) refers to amounts repayable after one year.

(i) Loan 1 is from a wholly owned subsidiary of the Company, Albedo Corporation Pte Ltd, and is unsecured and interest-free with no fixed repayment terms.

(ii) Loan 2 is from Dato' Ng Tian Sang @ Ng Kek Chuan who is the Deputy Chairman and CEO of the Company and a controlling shareholder of the Company. The loan, which bears interest rate of 8.00% per annum, is unsecured and not repayable within the next 12 months.

(iii) Loan 3 is from CIMB Bank Berhad. The CIMB Bank loan is procured in April 2020 for Beverly Bangsar Sdn Bhd operations. The term loan facility is secured by personal guarantees by certain directors of the Company. The term loan bears an interest rate of 3.5% per annum at Bank Negara Malaysia Funding Rate under Special Relief Facility calculated on a daily rest basis.

(iv) Loan 4 is from Kesavan Choo Ker Yong, an independent third party. The loan is unsecured, bears interest at 8.00% per annum and has a tenure of 12 months, with an automatic extension for a further 12 months.

14. Share capital

	Group and Company			
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
	No. of ordinary shares			
	'000	'000	**S$'000**	S$'000
Issued and paid up				
Beginning of financial period	**1,151,998**	632,869	**93,248**	87,630
Shares issued pursuant to: -				
Shares subscriptions	**25,683**[1]	229,809[4]	**275**	2,000
Professional fees	**8,772**[2]	11,111[5]	**100**	100
Consideration shares	**-**	186,566[6]	**-**	2,612
Share performance plan	**-**	5,525[7]	**-**	50
Debt capitalisation	**5,569**[3]	86,118[8]	**64**	814

Share issuance expenses	-	-	**(9)**	(54)
Expiry of warrants	-	-	-	96[9]
End of financial period	**1,192,022**	1,151,998	**93,678**	93,248

[1] On 29 January 2026, the Company completed the allotment and issuance of (i) 8,547,008 new ordinary shares at an issue price of S$0.0117 per share pursuant to the completion of the Leow Hoi Loong Subscription Share Issuance, (ii) 5,000,000 new ordinary shares at an issue price of S$0.0100 per share pursuant to the completion of the Tee Lay Yeong Subscription Share Issuance, (iii) 7,281,553 new ordinary shares at an issue price of S$0.0103 per share pursuant to the completion of the Lim Sin Khong Subscription Share Issuance and (iv) 4,854,368 new ordinary shares at an issue price of S$0.0103 per share pursuant to the completion of the Struys Leslie Oswin Subscription Share Issuance.

[2] On 29 January 2026, the Company completed the allotment and issuance of 8,771,929 new ordinary shares at an issue price of S$0.0114 per share pursuant to the completion of the Evolve Share Issuance in connection with the part payment of outstanding professional fees to Evolve Capital Advisory Private Limited.

[3] On 29 January 2026, the Company completed the allotment and issuance of 5,569,473 new ordinary shares at an issue price of S$0.0114 per share pursuant to the completion of the Cheah Sin Hing Debt Capitalisation.

[4] On 10 January 2025, the Company completed the allotment and issuance of (i) 24,096,385 new ordinary shares at an issue price of S$0.0083 per share pursuant to the completion of the Tan Chin Hong Subscription Share Issuance and (ii) 24,691,358 new ordinary shares at an issue price of S$0.0081 per share pursuant to the completion of the Lim Beoy Kee Subscription Share Issuance.

On 6 February 2025, the Company completed the allotment and issuance of 61,728,395 new ordinary shares at an issue price of S$0.0081 per share pursuant to the completion of the Mark Phillip Jones Subscription Share Issuance.

On 25 April 2025, the Company completed the allotment and issuance of 11,904,761 new ordinary shares at an issue price of S$0.0084 per share pursuant to the completion of the Leow Hoi Loong Subscription Share Issuance.

On 5 June 2025, the Company completed the allotment and issuance of (i) 12,195,121 new ordinary shares at an issue price of S$0.0082 per share pursuant to the completion of the Margaret Jean Smith Subscription Share Issuance and (ii) 57,471,264 new ordinary shares at an issue price of S$0.0087 per share pursuant to the completion of the Mark Phillip Jones Subscription Share Issuance.

On 18 November 2025, the Company completed the allotment and issuance of (i) 20,000,000 new ordinary shares at an issue price of S$0.0100 per share pursuant to the completion of the Khoo Poh Chye Subscription Share Issuance, (ii) 9,174,311 new ordinary shares at an issue price of S$0.0109 per share pursuant to the completion of the Tan Chin Hong Subscription Share Issuance and (iii) 8,547,008 new ordinary shares at an issue price of S$0.0117 per share pursuant to the completion of the Mageswari Subscription Share Issuance.

[5] On 10 January 2025, the Company completed the allotment and issuance of 11,111,111 new ordinary shares at an issue price of S$0.0090 per share pursuant to the completion of the Evolve Share Issuance in connection with the part payment of outstanding professional fees to Evolve Capital Advisory Private Limited.

[6] On 17 December 2025, the Company completed the allotment and issuance of 186,565,970 new ordinary shares at an issue price of S$0.0140 per share pursuant to the completion of the consideration shares issuance as part payment of the proposed acquisition of the second floor of Tower A of Nobel Healthcare Park.

(7) On 6 January 2025 and 8 October 2025, the Company completed the allotment and issuance of 2,777,778 and 2,747,252 new ordinary shares under the JCG Share Performance Plan, respectively.

(8) On 25 April 2025, the Company completed the allotment and issuance of 81,117,845 new ordinary shares at an issue price of S$0.0093 per share pursuant to the completion of the Debt Capitalisation.
On 18 November 2025, the Company completed the allotment and issuance of 5,000,000 new ordinary shares at an issue price of S$0.0120 per share pursuant to the completion of the Cheah Sin Hing Debt Capitalisation.

(9) During the financial period ended 30 September 2025, 4,540,540 unexercised non-transferrable warrants with an exercise price of S$0.047 per warrant expired on 9 March 2025. Accordingly, the warrant reserves were transferred to share capital upon the expiry and termination of the warrants.

Fully paid ordinary shares, which have no par value, carry one vote per share and a right to dividends as and when declared by the Company.

15. Significant events

On 21 September 2026, the Company announced that its subsidiary, Beverly Wilshire Medical Centre Sdn Bhd ("BWMCKL"), was served with a Writ and Statement of Claim by a patient alleging inter alia, medical malpractice said to have occurred in or around September 2025.

The patient is seeking special damages amounting to approximately MYR 961,386.44, together with general, aggravated and exemplary damages. Further to the Company's announcement dated 21 September 2026, BWMCKL's Malaysian solicitors filed a defence and counterclaim in relation to the suit on 27 October 2026.

BWMCKL has been informed by its collaboration partner, GY Beauty Aesthetic International Sdn Bhd that their authorised representatives have paid approximately MYR 500,000.00 towards the patient's medical expenses, and a further sum of about MYR 250,000.00 for inter alia accommodation, logistics expenses and other incidental expenses, as compensatory benefits and in settlement of the patient's claim.

The Company will make further announcement and keep its shareholders updated as and when there are material developments.

16. Events occurring after balance sheet date

There are no known subsequent events which have led to adjustments to this set of condensed interim consolidated financial statements.

F. OTHER INFORMATION PURSUANT TO APPENDIX 7C OF THE CATALIST RULES

1. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice

The figures for the financial period ended 30 September 2026 have not been audited or reviewed by the company's auditors.

2. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of matter)

Not applicable.

3. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

(a) updates on the efforts taken to resolve each outstanding audit issue; and
(b) confirmation from the Board that the impact of all outstanding audit issues on the financial statements has been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

The latest audited financial statements of the Group for the financial year ended 31 December 2025 were subject to a disclaimer of opinion. Please refer to Section E, note 2.3 of this Announcement and the announcement dated 10 April 2026 on the Disclaimer of Opinion by the Company's independent auditors on the financial statements for the financial year ended 31 December 2025, which was primarily in respect of the opening balances, going concern and impairment assessment. The disclaimer relating to the opening balances arose from the change of auditors in the previous financial year and is not expected to recur in subsequent financial years. In respect of the impairment assessment, the Management will continue to monitor the recoverability and performance of the relevant assets and will perform impairment reviews as required under the applicable accounting standards.

The Board confirms that the impact of all outstanding audit issues on the financial statements has been adequately disclosed.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

Except as disclosed in item 5 below, the accounting policies and methods of computation applied by the Group are consistent with those used in its most recently audited financial statements for the financial year ended 31 December 2025.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

For the current reporting period, new or revised financial reporting standards were issued by the Singapore Accounting Standards Council. Those applicable to the reporting entity are listed below.

Effective for the Group's annual periods beginning on or after 1 January 2026

- Amendments to SFRS(I) 10 and SFRS(I) 1-28: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
- Amendments to SFRS(I) 9 and SFRS(I) 7: Classification and Measurement of Financial Instruments
- Annual Improvements to SFRS(I)s
- SFRS(I) 18: Presentation and Disclosure in Financial Statements
- SFRS(I) 19: Subsidiaries without Public Accountability: Disclosures
- Amendments to SFRS(I) 9 and SFRS(I) 7: Contracts Referencing Nature-dependent Electricity

The Group does not expect any significant impact arising from the adoption of the above amendments to SFRS(I)s.

6. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the (a) current financial period reported on and (b) immediately preceding financial year

	Group		Company	
	As at 30 Sep 2026	As at 31 Dec 2025	**As at 30 Sep 2026**	As at 31 Dec 2025
Net asset value per ordinary share (cents)	**0.077**	0.089	**0.409**	0.422
Net assets (S$'000)	**922**	1,024	**4,871**	4,857
Number of ordinary shares used ('000)	**1,192,022**	1,151,998	**1,192,022**	1,151,998

7. Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends (a) based on the weighted average number of ordinary shares on issue and (b) on a fully diluted basis detailing any adjustments made to the earnings.

	Group			
	3 months ended		**9 months ended**	
	30 Sep 2026	30 Sep 2025	**30 Sep 2026**	30 Sep 2025
Profit/(Loss) attributable to equity holders of the Company (S$'000)	**(183)**	29	**(547)**	61
Weighted average number of ordinary shares ('000)	**1,192,022**	919,963	**1,187,918**	831,129
Profit/(Loss) per share (basic and diluted) (cents)	**(0.015)**	0.003	**(0.046)**	0.007

The basic and diluted profit/(loss) per share is the same as there were no potentially dilutive ordinary shares in issue as at 30 September 2026 and 30 September 2025.

The outstanding warrants were not included in the computation of the diluted profit/(loss) per share as their effect would have been anti-dilutive.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:

(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

REVIEW OF GROUP'S FINANCIAL PERFORMANCE

Revenue

	Group			
	3Q FY2026	3Q FY2025	Variance	
	S$'000	S$'000	S$'000	%
Aesthetic medical and healthcare	**1,283**	2,597	(1,314)	(51)

The Group registered a revenue of S$1.28 million for the third quarter ended 30 September 2026 ("**3Q FY2026**"), a decrease of S$1.3 million, or 51%, compared with the S$2.60 million recorded for the corresponding quarter ended 30 September 2025 ("**3Q FY2025**"). The decrease in the Group's revenue was attributed to the decrease in revenue from its aesthetic medical and healthcare segment.

Cost of sales decreased by 47% from S$1.13 million in 3Q FY2025 to S$0.60 million in 3Q FY2026, in line with the decrease in revenue.

Gross profit decreased by S$0.79 million from S$1.47 million in 3Q FY2025 to S$0.68 million in 3Q FY2026, mainly due to a decrease in the Group's revenue.

Other income increased to S$0.29 million in 3Q FY2026 from S$0.15 million in 3Q FY2025, mainly attributable to the write-back of amounts owing to a creditor that had been struck off the register, partially offset by the absence of rental income from the leasing of excess operating theatre capacity during the quarter.

Distribution expenses decreased by S$0.37 million from S$0.39 million in 3Q FY2025 to S$0.02 million in 3Q FY2026, mainly due to a decrease in marketing agency fees incurred. Administrative expenses remained relatively stable, decreasing marginally by S$0.02 million or 2%, from S$1.14 million in 3Q FY2025 to S$1.11 million in 3Q FY2026 Similarly, finance expenses remained largely unchanged with a marginal increase of S$0.001 million or 4%, from S$0.025 million in 3Q FY2025 to S$0.026 million in 3Q FY2026.

REVIEW OF GROUP'S FINANCIAL POSITION

Current assets decreased by 7%, from S$4.45 million as at 31 December 2025 to S$4.12 million as at 30 September 2026, mainly due to a decrease in inventories and cash and bank balances.

Non-current assets decreased by 9%, from S$1.25 million as at 31 December 2025 to S$1.14 million as at 30 September 2026. The decrease was mainly attributable to a reduction in property, plant and equipment, primarily arising from the depreciation of assets and reduction in right-of-use assets.

Current liabilities decreased by 12%, from S$4.43 million as at 31 December 2025 to S$3.89 million as at 30 September 2026, mainly attributable to a reduction in trade and other payables following the write-back of amount due to a creditor that had been struck off the register, as well as a decrease in lease liabilities arising from the impending expiry of certain lease arrangements.

Non-current liabilities increased by 19%, from S$1.10 million as at 31 December 2025 to S$1.31 million as at 30 September 2026, mainly due to increase in borrowing arising from Loan 4 obtained from Kesavan Choo Ker Yong, an independent third party.

REVIEW OF GROUP'S CASH FLOWS

Net cash used in operating activities amounted to S$0.26 million in 3Q FY2026, compared to net cash generated from operating activities of S$0.26 million in 3Q FY2025, mainly attributable to lower cash generated from operations.

Net cash generated from financing activities amounted to S$0.17 million in 3Q FY2026, primarily attributable to a net increase in borrowing of S$0.36 million, partially offset by the repayment of lease liabilities of S$0.19 million. Net cash flows used in investing activities were minimal during the quarter.

Consequently, overall cash and cash equivalents decreased by S$0.10 million in 3Q FY2026.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months

The global medical tourism market is anticipated to enjoy significant growth, surging from US$40.4 billion in 2024 to approximately US$207.9 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.8% over the period, according to Market.us Media. This expansion reflects a broader trend, whereby the demand for specialised medical treatments and aesthetic services across borders is intensifying[1].

In the Asia-Pacific region, the medical aesthetics market is expected to remain one of the fastest-growing segments within the healthcare industry. According to Data Bridge Market Research, the market is projected to grow at a compound annual growth rate (CAGR) of 13.8% through 2032[2], driven by rising disposable incomes, increasing consumer awareness, growing acceptance of minimally invasive procedures, technological advancements, and the continued expansion of medical tourism across the region.

Against this favorable industry backdrop and the Group's plans to commence operations at its newly acquired medical facilities in the fourth quarter of FY2026, the Group remains focused on strengthening its market position through the enhancement of its service offerings, expansion of its customer base, and continued investment in innovation. Leveraging its operational expertise and strategic capabilities, the Group will continue to pursue growth opportunities and adapt to evolving industry trends with the objective of delivering sustainable long-term growth and creating value for its stakeholders.

11. Dividend

If a decision regarding dividend has been made: -

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and

No dividend has been declared or recommended for the current financial period.

[1] Medical Tourism Market

[2] Asia-Pacific Medical Aesthetics Market – Industry Trends and Forecast to 2030

(b) (i) Amount per share (cents)

Not applicable

(ii) Previous corresponding period (cents)

Not applicable

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Not applicable

(d) The date the dividend is payable.

Not applicable

(e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.

Not applicable

12. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared or recommended for the financial period ended 30 September 2026 in view of the Group's operational and financial cash needs.

13. If the group has obtained a general mandate from shareholders for Interested Person Transactions ("IPT"), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company does not have any existing general mandate pursuant to Rule 920 of the Listing Rules. There were no disclosable Interested Person Transactions for the financial period ended 30 September 2026.

14. Updates on use of proceeds

(i) Khoo Poh Chye, Tan Chin Hong and Mageswari Rajoo share subscriptions

Use of Net Proceeds	Percentage Allocation (%)	Amount of Net Proceeds Allocated (S$)	Amount Utilised as at the date of this announcement (S$)	Balance of Net Proceeds as at the date of this announcement (S$)
For general working capital needs	100	400,000	400,000	-
Funding growth, development and expansion of its existing medical aesthetics and healthcare business and exploration of new business opportunities as and when they arise.	-	-	-	-

Total	**100**	**400,000**	**400,000**	**-**

The amount utilised for general working capital was used mainly in relation to manpower costs, professional fees and administrative expenses in accordance with the intended use stated in the announcements dated 28 August 2025, 24 September 2025, 30 September 2025, 27 February 2026, 30 March 2026 and Annual Report dated 10 April 2026.

(ii) Leow Hoi Loong, Tee Lay Yeong, Lim Sin Khong and Struys Leslie Oswin share subscriptions

Use of Net Proceeds	Percentage Allocation (%)	Amount of Net Proceeds Allocated (S$)	Amount Utilised as at the date of this announcement (S$)	Balance of Net Proceeds as at the date of this announcement (S$)
For general working capital needs	100	275,000	275,000	-
Funding growth, development and expansion of its existing medical aesthetics and healthcare business and exploration of new business opportunities as and when they arise.	-	-	-	-
Total	**100**	**275,000**	**275,000**	**-**

The amount utilised for general working capital was used mainly in relation to manpower costs, professional fees and administrative expenses in accordance with the intended use stated in the announcements dated 7 October 2025, 20 November 2025, 9 January 2026, 27 February 2026, 30 March 2026 and Annual Report dated 10 April 2026.

15. Negative confirmation pursuant to Rule 705(5) of the Catalist Rules.

The Board of Directors of the Company confirms that, to the best of their knowledge, nothing has come to the attention of the Board which may render the condensed interim consolidated financial statements for the nine-month financial period ended 30 September 2026 to be false or misleading in any material aspect.

16. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

The Company confirms that it has procured all the required undertakings from all its directors and executive officers in the format set out in Appendix 7H under Rule 720(1) of the Catalist Rules.

17. Disclosure on the acquisition or sale of shares pursuant to Rule 706A of the Catalist Rules.

Not applicable. There were no such acquisitions or sales of shares during the nine-month period from 1 January 2026 to 30 September 2026.

BY ORDER OF THE BOARD

Dato' Ng Tian Sang @ Ng Kek Chuan
Deputy Chairman and Chief Executive Officer

11 November 2026

This document has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Center, Singapore 068914.